Scancell Share Discussion Threads

[2tyke] 04/12/2024 20:28

Ooooh fragma I like your style. A cut above inane and co who have zero credibility.
Personally however ....I'm only interested in gains in the 1000's of %
Did I mention I follow Bitcoin ? 😂

[fragma] 04/12/2024 20:24

And anyone buying 12.5 years ago doubling their money !See how easy it is to make the facts suit your goal !

[2tyke] 04/12/2024 20:21

You can anticipate share price though inane ..well you can't...you don't know how 😂
Good old markingtime knows how to though.....Bitcoin absolutely soaring higher.
Markingtime knows his onions !
Love this bb...the posters are sooo clueless.

[inanaco] 04/12/2024 20:13

why does it affect my credibility ? I have not said dilution is "not possible" in fact i said "you cannot predict"

[2tyke] 04/12/2024 20:08

So tomorrow will see anyone buying this stock 12 years ago and holding losing 84% of their money.
That's how important trading really is.

[the real lozan] 04/12/2024 20:07

ZERO -
Not the S P...unless one of the SPIKED
BUT
Inane'n'co's credibilty is

[2tyke] 04/12/2024 19:55

Yes we know all that inane...
And as MT has spotted for us..Bitcoin is absolutely flying as outside events are totally irrelevant.

[inanaco] 04/12/2024 19:53

both work ..........they tested both with Covid

Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "Our preclinical studies have shown that delivery of SCOV1 and SCOV2 with the PharmaJet Needle-free Systems generate excellent T cell and antibody responses. In addition, they are easy to use and ideal for people who are needle phobic, an important cause of vaccine hesitancy. We look forward to progressing our COVIDITY-001 study in South Africa and updating the market in due course."

The data from the Phase 1 COVIDITY trial showed that neutralising antibodies were induced as well as T cell responses to both the receptor binding domain (RBD) of the spike protein and the nucleocapsid antigen (NCAP). In vaccine-naïve subjects, the seroconversion rate (the level of detectable antibodies in the blood due to vaccination) was 67% following SCOV1/SCOV2 vaccination, with a broad reactivity against multiple COVID-19 variants, including the currently dominant Omicron variant. These positive results demonstrate that SCOV1 and SCOV2, delivered via PharmaJet's needle-free injection device, induce immune responses in naïve participants. Additionally, a single dose of SCOV2 boosted broad responses in previously exposed subjects.

[2tyke] 04/12/2024 19:51

So glad I'm in crypto...and not risky little biotech.

[2tyke] 04/12/2024 19:49

Were all the other RNS's that also led to share price falls also due to dilution ?
Even when they had stacks of funds ?
All about intellectual honesty....you have it...or you don't !
The market is a place of irony...and..well you know the rest 😂

[nigelpm] 04/12/2024 19:48

Its stated in the rns. Q2 26

[supernumerary] 04/12/2024 19:42

It's done for a while, but it's only pocket money, so how long will it last?

[nigelpm] 04/12/2024 19:42

Perhaps the very news should make you realise that it wasn't dilution drivel. That should be your lesson from this. Listen to those that understand accounts and numbers.

[2tyke] 04/12/2024 19:41

Shame you couldn't spot it in advance chilly one....instead of hindsight 😂
Still your not a technician are you !

[inanaco] 04/12/2024 19:33

not concerned either, the good news we don't have to listen to dilution drivel going forward as they are looking to deal, i suspect the change in business sentiment is behind this, so yes in part it is linked to the current Gov.

[marcusl2] 04/12/2024 19:27

The Company expects that the net proceeds from the Placing and Subscription, in addition to the Company's existing cash resources (£9.1 million at close of business 1 November 2024) and the mid-single digit million US dollar upfront payment expected from Genmab following the recently announced exercise of Genmab's option to a second commercial license agreement, would provide sufficient capital to deliver the following clinical data and extension to the Company's cash runway:



• SCIB1 full cohort 1 objective response rate (ORR) data in 43 patients at 25 weeks;

• Modi-1 Renal Cell Carcinoma with double checkpoints ORR data in 19 patients (Simon Stage 1);

• continued iSCIB1+ cohort 3 recruitment, partnering / out-licensing discussions, and operational working capital;

• iSCIB1+ full cohort 3 intramuscular ORR data in 43 patients at 25 weeks;

• iSCIB1+ full cohort 4 intradermal ORR data in 43 patients at 25 weeks; and

• additional operational working capital to extend the cash runway to the second half of 2026 for partnering and out-licensing discussions.

It is intended that the net proceeds of the Retail Offer will be used to provide further working capital and balance sheet strength.

[chilltime] 04/12/2024 19:23

Well that explains holding it back on some solid news the good old market knew.

It’s done now, annoying on timing, but no great dilution.

[2tyke] 04/12/2024 19:13

Yes big close coming MT (clown).
Shame your not in something flying like Bitcoin !

All in the EW patterns like I spotted weeks ago for you.
When the share price is heading lower ....it's heading lower. NO good news can alter this.
The difference between being a technical trader, and a 'dreamer' is astronomical.

[inanaco] 04/12/2024 19:05

Modi-1 Renal Cell Carcinoma with double checkpoints ORR data in 19 patients (Simon Stage 1)


interesting early release of data which we did not see in ISCIB1 ... now added to potential RNS short term

[inanaco] 04/12/2024 19:02

back testing ISCIB1 ... adding another Cohort of 43 via two different delivery its not a change of gun just the area of interest. and no discussions of partnering with SCIB1 ..... but moved to ISCIB1 ...

whats clear is They are going to do a Deal .... on Iscib1 and they want all the permutations of using both routes of delivery tested in a larger cohort

interesting



• SCIB1 full cohort 1 objective response rate (ORR) data in 43 patients at 25 weeks;

• Modi-1 Renal Cell Carcinoma with double checkpoints ORR data in 19 patients (Simon Stage 1);

• continued iSCIB1+ cohort 3 recruitment, partnering / out-licensing discussions, and operational working capital;

• iSCIB1+ full cohort 3 intramuscular ORR data in 43 patients at 25 weeks;

• iSCIB1+ full cohort 4 intradermal ORR data in 43 patients at 25 weeks; and

• additional operational working capital to extend the cash runway to the second half of 2026 for partnering and out-licensing discussions.

It is intended that the net proceeds of the Retail Offer will be used to provide further working capital and balance sheet strength.

[nigelpm] 04/12/2024 18:51

And there we go. Financing sorted albeit not in an ideal manner but that's the way it goes.

[ivyspivey] 04/12/2024 18:51

Hi Moljen yep Loggie proved prophetic even if it was a different route to 11p.
Feel sorry for anyone who bought in this morning and anybody who pretends SCLP is any different to its treatment of SH than anyone else has their answer.
Just glad I am not holding 1.6m shareshares

[echelon] 04/12/2024 18:38

The Board running a pump & dump exercise against the shareholders. Spiked again. Is Reeves on the Board?

[moljen] 04/12/2024 18:15

Well done Loggie - you did say would be 11p.

Not too sure you were thinking it would be achieved by the Company screwing over its long suffering shareholders yet again.

Don't worry some Director is putting in a paltry £20K so all is good, what's the betting there will be accompanying share options being granted over a huge chunk of shares to make up for it?